^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MYC rearrangement

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
11ms
Diffuse Large B-Cell Lymphoma/High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements: a study of 60 Cases. (PubMed, Mod Pathol)
Following induction with R-CHOP chemotherapy, BCL6-DHL patients demonstrated a poor OS similar to BCL2-DHL patients and worse than that of DLBCL patients (p = 0.024)...The data also suggest that BCL6-DHL as currently defined, is heterogeneous and that neoplasms with a GCB immunophenotype are more likely to have DH-like signature and behave more aggressively. Lastly, we suggest that BCL6-DHL cases deserve to be recognized separately in a lymphoma classification to facilitate further understanding of these neoplasms and for optimal patient management.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL2 expression • MYC expression • MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab)
11ms
High-Risk MCL: Recognition and Treatment. (PubMed, Blood)
These findings necessitate revisiting the prognostic impact of high-risk factors, current management strategies, new bi- and tri-specific T-cell engagers, combination therapies, novel therapeutic targets, and next-generation clinical trials for high-risk MCL patients. This article provides a comprehensive update on recognizing and managing high-risk MCL, encompassing current practices and future directions.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • CD70 (CD70 Molecule) • SP140 (SP140 Nuclear Body Protein) • MSI2 (Musashi RNA Binding Protein 2) • NFKBIE (NFKB Inhibitor Epsilon) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • MYC rearrangement
11ms
Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas. (PubMed, Br J Haematol)
Gene expression profiling showed a significant overlap between 'early lesions' and polymorphic PTLD. The presence of clonal haematopoiesis of indeterminate potential (CHIP)-like mutations and the absence of immune-escape gene mutations in 'early lesions' suggest these disorders may represent clonal expansions driven by exogenic immunosuppression and/or EBV infection 'substituting' for mutations of the latter group of genes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
TP53 mutation • NOTCH1 mutation • MYC rearrangement • CD8-H
12ms
Pediatric Orbital High-Grade B-Cell Lymphoma: A Case Report and Review of the Literature. (PubMed, Ophthalmic Plast Reconstr Surg)
Herein we present a unique case of orbital high-grade B-cell lymphoma in a pediatric patient, initially diagnosed as preseptal cellulitis. Careful observation and escalation of care ultimately led to the accurate diagnosis and complete remission of the disease.
Review • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement • BCL2 rearrangement
12ms
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=130, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Jul 2029 | Trial primary completion date: Mar 2025 --> Jul 2024
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement
|
Venclexta (venetoclax) • prednisone • enitociclib (VIP152)
12ms
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=130, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement
|
Venclexta (venetoclax) • prednisone • enitociclib (VIP152)
12ms
Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration. (PubMed, Ann Hematol)
To the best of our knowledge, this is the first reported case of AITL with TCR::MYC rearrangement. This condition could be associated with refractoriness to chemotherapy and aggressive clinical course with systemic infiltration that included the intestine.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC rearrangement • MYC translocation
12ms
How I diagnose high-grade B-cell lymphoma. (PubMed, Am J Clin Pathol)
High-grade B-cell lymphomas are subclassified based on morphologic and genetic features. There are differences in the nomenclature and definition of these lymphomas in the WHO-5 and ICC classifications. Distinguishing HGBLs from other mature B-cell lymphomas and B-LBL/ALL is critical so that patients receive appropriate treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL2 expression • MYC expression • MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
12ms
CARTHEDRALL: CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (clinicaltrials.gov)
P1/2, N=81, Recruiting, University of Sao Paulo | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2)
|
CD19 positive • MYC rearrangement • CD19 expression